MAP2 and schizophrenia: Moreover, a lack of MAP2 immunoreactivity has also been described in brain samples from individuals with schizophrenia [48], which did not correspond with the results of MAP2 detection by proteomic techniques where no decrease in MAP2 expression was detected in those same samples [47, 49].